دورية أكاديمية
أعرض في EDS

CD3bright signals on γδ T cells identify IL-17A-producing Vγ6Vδ1+ T cells.

التفاصيل البيبلوغرافية
العنوان: CD3bright signals on γδ T cells identify IL-17A-producing Vγ6Vδ1+ T cells.
المؤلفون: Paget C; 1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia [3] INSERM U1019, Centre d'Infection et d'Immunité de Lille, Institut Pasteur de Lille, Lille, France [4] University of Lille 2, Lille, France., Chow MT; 1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia [3] QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia., Gherardin NA; 1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia [3] Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria, Australia., Beavis PA; 1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia., Uldrich AP; Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria, Australia., Duret H; 1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia., Hassane M; 1] INSERM U1019, Centre d'Infection et d'Immunité de Lille, Institut Pasteur de Lille, Lille, France [2] University of Lille 2, Lille, France., Souza-Fonseca-Guimaraes F; QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia., Mogilenko DA; 1] University of Lille 2, Lille, France [2] INSERM U1011, Institut Pasteur de Lille, Lille, France [3] European Genomic Institute of Diabetes, Lille, France., Staumont-Sallé D; 1] University of Lille 2, Lille, France [2] INSERM U1011, Institut Pasteur de Lille, Lille, France [3] European Genomic Institute of Diabetes, Lille, France [4] Department of Dermatology, Claude Huriez Hospital, Lille, France., Escalante NK; Department of Immunology, University of Toronto, Toronto, Ontario, Canada., Hill GR; 1] QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia [2] Department of Bone Marrow Transplantation, Royal Brisbane Hospital, Herston, Queensland, Australia., Neeson P; 1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia., Ritchie DS; 1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia., Dombrowicz D; 1] University of Lille 2, Lille, France [2] INSERM U1011, Institut Pasteur de Lille, Lille, France [3] European Genomic Institute of Diabetes, Lille, France., Mallevaey T; Department of Immunology, University of Toronto, Toronto, Ontario, Canada., Trottein F; 1] INSERM U1019, Centre d'Infection et d'Immunité de Lille, Institut Pasteur de Lille, Lille, France [2] University of Lille 2, Lille, France., Belz GT; Division of Molecular Immunology, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia., Godfrey DI; 1] Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria, Australia [2] Australian Research Council Centre of Excellence in Advanced Medical Imaging at University of Melbourne, Parkville, Victoria, Australia., Smyth MJ; 1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia [3] QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia [4] School of Medicine, University of Queensland, Herston, Queensland, Australia.
المصدر: Immunology and cell biology [Immunol Cell Biol] 2015 Feb; Vol. 93 (2), pp. 198-212. Date of Electronic Publication: 2014 Nov 11.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
اللغة: English
بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 8706300 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1440-1711 (Electronic) Linking ISSN: 08189641 NLM ISO Abbreviation: Immunol Cell Biol Subsets: MEDLINE
أسماء مطبوعة: Publication: 2018- : [Hoboken, NJ] : Wiley
Original Publication: [Adelaide, South Australia] : University of Adelaide, [c1987-
مواضيع طبية MeSH: CD3 Complex/*metabolism , Interleukin-17/*biosynthesis , Receptors, Antigen, T-Cell, gamma-delta/*metabolism , T-Lymphocytes/*immunology, Amino Acid Sequence ; Aminoquinolines/pharmacology ; Animals ; CD3 Complex/chemistry ; Carrier Proteins/metabolism ; Germ Cells/drug effects ; Homeostasis/drug effects ; Imiquimod ; Immunity ; Inflammasomes/drug effects ; Inflammasomes/metabolism ; Interleukin-1beta/metabolism ; Interleukin-23 ; Lung/drug effects ; Lung/immunology ; Lymphocyte Subsets/drug effects ; Lymphocyte Subsets/immunology ; Male ; Mice, Inbred C57BL ; Molecular Sequence Data ; NLR Family, Pyrin Domain-Containing 3 Protein ; Nuclear Receptor Subfamily 1, Group F, Member 3/metabolism ; Phenotype ; Skin/drug effects ; Skin/immunology ; T-Lymphocytes/drug effects
مستخلص: Interleukin-17A (IL-17A) is a pro-inflammatory cytokine that has an important role at mucosal sites in a wide range of immune responses including infection, allergy and auto-immunity. γδ T cells are recognized as IL-17 producers, but based on the level of CD3 expression, we now define the remarkable ability of a CD3(bright) γδ T-cell subset with an effector memory phenotype to rapidly produce IL-17A, but not interferon-γ. CD3(bright) γδ T cells uniformly express the canonical germline encoded Vγ6/Vδ1(+) T-cell receptor. They are widely distributed with a preferential representation in the lungs and skin are negatively impacted in the absence of retinoic acid receptor-related orphan receptor gammat expression or endogenous flora. This population responded rapidly to various stimuli in a mechanism involving IL-23 and NOD-like receptor family, pyrin domain containing 3 (NLRP3)-inflammasome-dependent IL-1β. Finally, we demonstrated that IL-17-producing CD3(bright) γδ T cells responded promptly and strongly to pneumococcal infection and during skin inflammation. Here, we propose a new way to specifically analyze IL-17-producing Vγ6/Vδ1(+) T cells based on the level of CD3 signals. Using this gating strategy, our data reinforce the crucial role of this γδ T-cell subset in respiratory and skin disorders.
References: Ann N Y Acad Sci. 2012 Jan;1247:34-45. (PMID: 22239719)
J Immunol. 1995 Apr 15;154(8):3814-20. (PMID: 7706721)
Nature. 1988 Feb 18;331(6157):627-31. (PMID: 2963227)
Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4942-7. (PMID: 15037737)
J Immunol. 2006 Oct 1;177(7):4662-9. (PMID: 16982905)
Vaccine. 2010 Jul 12;28(31):5068-74. (PMID: 20478344)
J Exp Med. 2011 Mar 14;208(3):491-503. (PMID: 21383056)
Nucleic Acids Res. 1998 Jan 1;26(1):297-303. (PMID: 9399859)
Nat Rev Immunol. 2010 Jul;10(7):479-89. (PMID: 20559326)
Nat Immunol. 2008 Jun;9(6):641-9. (PMID: 18454151)
Cell. 2006 Sep 22;126(6):1121-33. (PMID: 16990136)
Immunity. 2009 Aug 21;31(2):331-41. (PMID: 19682929)
Eur J Immunol. 2012 Sep;42(9):2221-31. (PMID: 22949320)
Eur J Immunol. 2009 Dec;39(12):3488-97. (PMID: 19830744)
Eur J Immunol. 2005 Apr;35(4):1292-300. (PMID: 15770699)
Clin Exp Immunol. 2009 Sep;157(3):385-94. (PMID: 19664147)
J Clin Invest. 2010 May;120(5):1762-73. (PMID: 20364087)
J Immunol. 2009 Jun 15;182(12):7348-51. (PMID: 19494256)
Blood. 2009 Jun 25;113(26):6611-8. (PMID: 19395673)
Immunity. 2007 Oct;27(4):597-609. (PMID: 17950005)
J Clin Invest. 2013 Oct;123(10):4364-74. (PMID: 24051381)
Immunology. 2008 Oct;125(2):170-7. (PMID: 18397272)
J Leukoc Biol. 2004 Jan;75(1):68-75. (PMID: 14525969)
Eur J Immunol. 2010 Sep;40(9):2391-400. (PMID: 20690180)
Immunity. 2004 Oct;21(4):467-76. (PMID: 15485625)
Immunity. 2009 Aug 21;31(2):181-3. (PMID: 19699169)
Immunol Lett. 2009 Dec 2;127(1):8-12. (PMID: 19682496)
Blood. 2011 Jul 7;118(1):129-38. (PMID: 21505189)
EMBO J. 1993 Dec;12(12):4863-75. (PMID: 8223495)
J Immunol. 2009 May 15;182(10):6540-9. (PMID: 19414809)
Semin Immunol. 2009 Apr;21(2):84-91. (PMID: 19298946)
Infect Immun. 2011 Nov;79(11):4503-10. (PMID: 21875963)
Immunity. 2013 Jul 25;39(1):184-95. (PMID: 23890071)
Cell Mol Immunol. 2008 Jun;5(3):203-8. (PMID: 18582402)
Eur J Immunol. 2009 May;39(5):1231-40. (PMID: 19350552)
Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17549-54. (PMID: 23047700)
Nature. 1986 Aug 28-Sep 3;322(6082):836-40. (PMID: 2943999)
J Exp Med. 2007 May 14;204(5):995-1001. (PMID: 17470641)
J Immunol. 2011 May 15;186(10 ):5738-48. (PMID: 21471445)
Trends Immunol. 2012 Sep;33(9):459-66. (PMID: 22677185)
J Immunol. 2007 Apr 1;178(7):4466-72. (PMID: 17372004)
Immunity. 2012 Jul 27;37(1):48-59. (PMID: 22770884)
J Immunol. 2010 Apr 15;184(8):4055-61. (PMID: 20368285)
Immunity. 2010 Nov 24;33(5):736-51. (PMID: 21093318)
Immunity. 2009 Aug 21;31(2):321-30. (PMID: 19682928)
J Exp Med. 1992 Jan 1;175(1):203-9. (PMID: 1530959)
Immunity. 2011 Jul 22;35(1):59-68. (PMID: 21737317)
Blood. 2011 Jul 21;118(3):586-93. (PMID: 21606479)
Nat Immunol. 2009 Apr;10(4):427-36. (PMID: 19270712)
J Immunol. 2012 Apr 15;188(8):3928-39. (PMID: 22412194)
Cell Immunol. 2008 Jan;251(1):50-5. (PMID: 18423430)
Nat Med. 2011 Jun 12;17(7):837-44. (PMID: 21666695)
J Allergy Clin Immunol. 2009 May;123(5):986-94; quiz 995-6. (PMID: 19410688)
Nature. 1990 Feb 22;343(6260):754-7. (PMID: 2154700)
J Immunol. 2009 May 15;182(10):6435-43. (PMID: 19414797)
Immunity. 2011 Oct 28;35(4):596-610. (PMID: 21982596)
J Immunol. 2014 Apr 1;192(7):2975-83. (PMID: 24600030)
Cytokine Growth Factor Rev. 2010 Dec;21(6):443-8. (PMID: 21095154)
J Immunol. 2009 May 1;182(9):5836-45. (PMID: 19380832)
J Infect Dis. 2012 Sep 1;206(5):723-34. (PMID: 22723642)
Immunol Cell Biol. 2011 Aug;89(6):739-46. (PMID: 21263463)
Arthritis Rheum. 2012 May;64(5):1420-9. (PMID: 22144400)
Nat Rev Immunol. 2010 Jul;10(7):467-78. (PMID: 20539306)
Cell Host Microbe. 2010 Feb 18;7(2):140-50. (PMID: 20159619)
Semin Immunol. 2010 Aug;22(4):193-8. (PMID: 20451408)
J Immunol. 2009 Oct 1;183(7):4169-75. (PMID: 19767566)
المشرفين على المادة: 0 (Aminoquinolines)
0 (CD3 Complex)
0 (Carrier Proteins)
0 (Inflammasomes)
0 (Interleukin-17)
0 (Interleukin-1beta)
0 (Interleukin-23)
0 (NLR Family, Pyrin Domain-Containing 3 Protein)
0 (Nlrp3 protein, mouse)
0 (Nuclear Receptor Subfamily 1, Group F, Member 3)
0 (Receptors, Antigen, T-Cell, gamma-delta)
0 (T-cell receptor Vgamma6, mouse)
P1QW714R7M (Imiquimod)
تواريخ الأحداث: Date Created: 20141112 Date Completed: 20151214 Latest Revision: 20220410
رمز التحديث: 20221213
DOI: 10.1038/icb.2014.94
PMID: 25385067
قاعدة البيانات: MEDLINE
الوصف
تدمد:1440-1711
DOI:10.1038/icb.2014.94